Certara, Inc. $CERT Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its position in Certara, Inc. (NASDAQ:CERT) by 133.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,272,823 shares of the company’s stock after buying an additional 1,299,109 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 1.43% of Certara worth $20,024,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. Associated Banc Corp increased its stake in Certara by 9.7% during the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock worth $146,000 after acquiring an additional 1,051 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares in the last quarter. Corient Private Wealth LLC grew its holdings in shares of Certara by 11.1% during the 2nd quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock worth $144,000 after purchasing an additional 1,232 shares during the period. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Certara by 2.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after purchasing an additional 1,597 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Certara stock opened at $5.75 on Friday. The firm has a market capitalization of $915.06 million, a PE ratio of -575.00 and a beta of 1.50. Certara, Inc. has a one year low of $5.72 and a one year high of $15.38. The stock’s 50 day moving average price is $7.35 and its 200 day moving average price is $9.31. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same period last year, the business earned $0.15 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Stephens cut their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research note on Monday, December 29th. Barclays reissued an “equal weight” rating and issued a $8.00 price objective on shares of Certara in a research report on Friday, March 6th. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Certara in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $11.10.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.